Skip to main content
Thomas Uldrick Jr., MD, Oncology, Seattle, WA

ThomasUldrickJr.MD

Oncology • Seattle, WA

Deputy Head, Global Oncology

Join to view full profile

Dr. Uldrick is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Uldrick's full profile

Already have an account?

  • Office

    1100 Fairview Ave N
    Mail Stop M1-B140
    Seattle, WA 98109
    Phone+1 206-667-7485
    Fax+1 206-667-1965

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2005 - 2008
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2002 - 2005
  • State University of New York Downstate Medical Center College of Medicine
    State University of New York Downstate Medical Center College of MedicineClass of 2002

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2017 - 2026
  • NY State Medical License
    NY State Medical License 2004 - 2021

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Discovery of Kaposi’s Sarcoma Herpesvirus-Encoded Circular RNAs and a Human Antiviral Circular RNA  
    Ramya Ramaswami, Kathryn Lurain, Thomas S Uldrick, Proceedings of the National Academy of Sciences
  • International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease  
    Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood

Abstracts/Posters

  • Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients...
    Thomas S. Uldrick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials
    Thomas S. Uldrick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV
    Thomas S. Uldrick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Phase I study of pembrolizumab in people with HIV and cancer. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Pathologic Misdiagnosis in Children with Suspected Burkitt Lymphoma Associated with Early MortalityClinically Relevant Abstract 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Cancer Immunotherapy Flushes HIV Out of Hiding
    Cancer Immunotherapy Flushes HIV Out of HidingFebruary 9th, 2022
  • Cancer Drug Flushes Out Latent HIV, Exciting New Study Finds
    Cancer Drug Flushes Out Latent HIV, Exciting New Study FindsJanuary 28th, 2022
  • Anti-Cancer Drug Can Flush Out HIV Hiding in Cells, Study Suggests
    Anti-Cancer Drug Can Flush Out HIV Hiding in Cells, Study SuggestsJanuary 27th, 2022
  • Join now to see all

Professional Memberships

Dr. Thomas Uldrick, Dr. Thomas Uldrick, MD, Dr. T Uldrick